Risedronate Sodium Tablet, Film Coated
Product Images NDC 0093-3099

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 0093-3099). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 1)

Chemical structure of Risedronate Sodium showing its molecular arrangement including phosphate groups, a pyridine ring, and hydration with one water molecule (H2O).*

FDA Label Image

Carton 1 Of 2 (Image 10)

Risedronate Sodium 35 mg once-a-week tablets, film-coated oral dosage form. The packaging label shows a 4-week supply containing 4 tablets. Manufactured by Teva Pharmaceuticals USA, Inc. The label includes usage instructions and barcode.*

FDA Label Image

Figure 1 (Image 2)

A bar chart comparing the percentage of patients by fracture sites between those taking a placebo and those taking Risedronate Sodium Tablets 5 mg. The chart shows data for fracture locations including all sites, wrist, humerus, hip, pelvis, leg, and clavicle, with distinct bars for placebo and Risedronate Sodium groups.*

FDA Label Image

Figure 2 (Image 3)

A bar chart comparing mean percentage change in bone mineral density (BMD) with standard error (SE) for the lumbar spine, femoral neck, and femoral trochanter. It contrasts placebo results with results for Risedronate Sodium Tablets 5 mg in study groups of varying sizes (n).*

FDA Label Image

Figure 3 (Image 4)

A bar chart comparing the mean percent change ± SE in bone mineral density (BMD) at three anatomical sites (Lumbar Spine, Femoral Neck, Femoral Trochanter) between placebo and Risedronate Sodium Tablets 5 mg groups. Sample sizes for each group at each site are indicated above the bars.*

FDA Label Image

Figure 4 (Image 5)

A bar graph comparing the mean percentage change ± standard error in bone mineral density (BMD) at the lumbar spine, femoral neck, and femoral trochanter between placebo and Risedronate Sodium Tablets 5 mg groups.*

FDA Label Image

Figure 5 (Image 6)

A bar chart comparing the incidence percentage of an unspecified outcome between placebo and Risedronate Sodium Tablets 5 mg groups. The chart shows three categories: patients continuing glucocorticoid treatment, patients initiating glucocorticoid treatment, and a combined group. Each category displays sample sizes (n) for both placebo and treatment groups.*

FDA Label Image

Figure 6 (Image 7)

A line graph comparing the percentage change over visit days up to 600 days between Risedronate Sodium Tablets 30 mg and Etidronate Disodium Tablets 400 mg. The x-axis represents visit days divided into Treatment, Follow-Up, and Extended Follow-Up phases. The y-axis shows percentage change with error bars and sample sizes (n) indicated for each phase.*

FDA Label Image

5 mg Container Label (Image 8)

Label for Risedronate Sodium Tablets, USP 5 mg oral film-coated tablets, supplied in a package of 30 tablets. The label includes NDC 0093-3099-56 and states it is manufactured in Israel by Teva Pharmaceutical Ind. Ltd and for Teva Pharmaceuticals in Parsippany, NJ. It features storage, handling, and dispensing instructions along with a serialization coding area and the Teva logo.*

FDA Label Image

30 mg Container Label (Image 9)

Risedronate Sodium Tablets, USP 30 mg film-coated oral tablets in a package of 30 tablets by Teva Pharmaceuticals USA, Inc. The label includes NDC 0093-3100-56, serialization coding area, manufacturer information, dosing instructions, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.